Temozolomide

Title: Phase II study of oral Temozolomide for Soft Tissue Sarcoma

Eligibility Requirements:
Unresectable, recurrent or metastatic disease.
No more than one prior chemotherapy regimen.
Prior Dacarbazine is permitted.
Prior surgery and/or radiation therapy allowed.

This outpatient treatment will be administered orally, twice a day for 5 days per week during a twenty-eight day cycle.

CPT-11

Title: Phase II Study of CPT 11 in Previously Treated Advanced Sarcoma.

Eligibility Requirements:
Soft tissue sarcoma distantly metastatic, unresectable locally advanced or recurrent disease.
Received one but not more than two prior chemotherapy regimens.

Outpatient intravenous chemotherapy.

Cardiac Transplantation

Title: Phase II Study of Cardiac Transplantation for Primary Cardiac Sarcomas.

Trial is under development at the present time.

Eligibility Requirements:
Patients must have biopsy proven primary cardiac sarcoma, with no evidence of metastatic disease. Patients will be evaluated by both the medical oncologist and transplant team. In most cases patients will be treated with three courses of chemotherapy prior to transplantation.

Gemcitabine

Title: Phase II Study in Collaboration with the Southwest Oncology Group of Gemcitabine in Advanced Soft Tissue Sarcoma

Eligibility Requirements:

Soft tissue sarcoma unresectable primary or metastatic disease.
Patients must have received no prior gemcitabine.
Prior adjuvant chemotherapy so long as relapse has not occurred within 6 months of the last dose of adjuvant chemotherapy.

Bone Marrow Transplant

Title: Phase II Study of high Dose Chemotherapy in Inoperable or
Metastatic Sarcoma.

Eligibility Requirements:
Inoperable or Metastatic Sarcoma Evaluation by a Columbia University Bone marrow Transplantation Unit Attending.
Muga >45%.
High dose Chemotherapy Followed by bone Marrow or Stem Cell Transplantation.
Treatment will be via intravenous infusion weekly as an outpatient.